8-K: Phathom Pharmaceuticals Reports Strong Q2 Growth

Phathom Pharmaceuticals announced robust second-quarter 2025 financial results, driven by significant VOQUEZNA prescription growth and a refined commercial strategy, reaffirming its path to profitability in 2026.

Summary

• Net revenues for Q2 2025 reached $39.5 million, a substantial increase from $7.3 million in Q2 2024.
• Over 580,000 VOQUEZNA prescriptions have been filled to date through July 25, 2025, marking a 49% growth since the last earnings report.
• Approximately 173,000 VOQUEZNA prescriptions were filled in Q2 2025, representing 36% sequential growth from Q1.
• Prescriber adoption expanded to over 29,300 unique healthcare providers as of July 18, 2025, a 24% increase.
• The company initiated a strategic shift in early July 2025, reprioritizing gastroenterologists (GIs) in its sales strategy, who currently account for approximately 70% of all filled VOQUEZNA prescriptions.
• FDA updated the Orange Book in June 2025, reflecting 10-year New Chemical Entity (NCE) exclusivity for VOQUEZNA 10 mg and 20 mg tablets through May 2032, making generic entry unlikely before 2033.
• Net loss for Q2 2025 was $75.8 million, an improvement from $91.4 million in Q2 2024.
• Non-GAAP operating expenses for Q2 2025 were $86.1 million, a sequential decrease from $98.1 million in Q1 2025, attributed to cost savings from restructuring efforts.
• Phathom expects non-GAAP operating expenses to be less than $60 million for Q3 2025 and less than $55 million for Q4 2025.
• Full-year 2025 revenue guidance is set between $165 million and $175 million.
• Cash and cash equivalents stood at $149.6 million as of June 30, 2025, which the company believes is sufficient to fund operations and achieve profitability in 2026 (excluding stock-based compensation).

Sentiment

Score: 8

Explanation: The filing indicates strong commercial progress for VOQUEZNA with significant revenue and prescription growth, coupled with strategic cost reductions and extended market exclusivity. The company has a clear path to profitability in 2026 and provides positive full-year revenue guidance. While still operating at a net loss and experiencing a decrease in cash, the overall trajectory and management's confidence suggest a very positive outlook.

Positives

• Significant year-over-year revenue growth, with Q2 2025 net revenues of $39.5 million compared to $7.3 million in Q2 2024.
• Strong sequential prescription growth for VOQUEZNA, with 173,000 prescriptions filled in Q2 2025, a 36% increase from Q1.
• Total VOQUEZNA prescriptions filled to date surpassed 580,000, reflecting 49% growth since the last earnings report.
• Expanded prescriber adoption with over 29,300 unique healthcare providers, a 24% increase.
• Successful implementation of strategic cost reductions, leading to a sequential decrease in operating expenses.
• Extended market exclusivity for VOQUEZNA through May 2032, with generic entry unlikely before 2033, providing long-term revenue protection.
• Reduced net loss in Q2 2025 ($75.8 million) compared to Q2 2024 ($91.4 million).
• Company remains focused on and projects a clear path to profitability in 2026.
• Provided strong full-year 2025 revenue guidance of $165 million to $175 million.
• Cash and cash equivalents of $149.6 million are deemed sufficient to fund operations to profitability in 2026.

Negatives

• Continued significant net loss of $75.8 million in Q2 2025, despite improvement from the prior year.
• Cash and cash equivalents decreased significantly to $149.6 million as of June 30, 2025, from $297.263 million as of December 31, 2024.
• Increased R&D expenses ($9.1 million in Q2 2025 vs. $7.4 million in Q2 2024) primarily due to one-time personnel-related restructuring charges.
• Increased SG&A expenses ($85.3 million in Q2 2025 vs. $75.9 million in Q2 2024) due to one-time restructuring charges and continued commercial investment.

Risks

• Inability to successfully commercialize VOQUEZNA or achieve expected revenue levels.
• The market opportunity for VOQUEZNA may be significantly smaller than anticipated.
• Market acceptance for VOQUEZNA from healthcare professionals, patients, and payors may be significantly lower than expected.
• Potential encounter of coverage, reimbursement, market access, or other issues that may negatively impact commercialization efforts.
• The unmet need for new treatment options in GERD may not be as high as anticipated.
• Estimates of patient numbers and potential market size may not be accurate.
• Resource allocation decisions may not lead to expected results.
• Failure to seek, achieve, or maintain expected patent and regulatory exclusivity, potentially leading to earlier generic competition.
• Negative impact from the launch of other competitive products.
• Adverse impact due to dependence on third parties for commercialization, manufacturing, research, and clinical testing.
• Negative impact from regulatory developments or other governmental actions, including healthcare reform.
• Unexpected adverse side effects or inadequate efficacy of VOQUEZNA, potentially limiting market acceptance, impairing development/approvals, or resulting in recalls/product liability claims.
• Inability to obtain and maintain intellectual property protection important to the business, including patent term extensions.
• Breach of the license agreement with Takeda for vonoprazan could significantly impair the business.
• Operating expenses may be higher than anticipated due to unexpected activities or expenses, including litigation.
• May not achieve profitability on expected timelines or at all.
• Potential future insufficiency of cash to fund operations or meet obligations, potentially requiring additional capital.
• Inability to raise additional capital on acceptable terms.

Future Outlook

Phathom Pharmaceuticals expects full-year 2025 revenue to be in the range of $165 million to $175 million, driven by strong VOQUEZNA prescription trends and a refined commercial strategy. The company remains focused on achieving profitability from operations in 2026, excluding stock-based compensation, and anticipates non-GAAP operating expenses to decrease to less than $60 million for Q3 2025 and less than $55 million for Q4 2025. Generic entry for VOQUEZNA is considered unlikely before 2033 due to extended NCE exclusivity.

Management Comments

• "The second quarter marked a significant step forward in Phathom's journey toward becoming a growth-oriented and profitable GI company."
• "We delivered strong sequential revenue growth, implemented strategic cost reductions, and shifted our commercial strategy to focus on high-value prescribers."
• "With over 580,000 VOQUEZNA prescriptions filled to date and extended market exclusivity, we believe we are well-positioned to accelerate VOQUEZNA's adoption and achieve profitability in 2026."

Industry Context

Phathom Pharmaceuticals operates in the highly competitive gastrointestinal (GI) disease market, focusing on novel treatments like VOQUEZNA, a first-in-class potassium-competitive acid blocker (PCAB). The company's strategic shift to prioritize gastroenterologists (GIs) reflects a common industry practice of targeting high-prescribing specialists for new drug adoption, especially in complex disease areas. The extended FDA New Chemical Entity (NCE) exclusivity for VOQUEZNA provides a significant competitive advantage by delaying generic competition, a critical factor for biopharmaceutical companies seeking to maximize returns on R&D investments. The focus on profitability in 2026 aligns with a broader trend in the biotech sector where companies transition from development-heavy, cash-burning phases to commercial-stage, revenue-generating entities.

Management Changes

Stakeholder Impact

• **Shareholders**: Positive impact due to strong revenue growth, reduced net loss, extended market exclusivity for VOQUEZNA, and a clear path to profitability in 2026. The strategic shift and cost reductions aim to improve financial performance and shareholder value. However, the decrease in cash and potential need for future capital raises could be a concern.
• **Employees**: Impacted by one-time personnel-related restructuring charges, indicating some workforce adjustments. The strategic shift in sales focus may also affect roles and responsibilities within the commercial team.
• **Customers (Healthcare Providers and Patients)**: Continued robust commercial access for VOQUEZNA (over 120 million lives covered) ensures availability. The focus on high-value prescribers aims to deepen engagement and improve adoption, potentially benefiting patients needing VOQUEZNA.
• **Suppliers**: No direct impact mentioned, but continued commercial success and manufacturing needs for VOQUEZNA would benefit suppliers.
• **Creditors**: The company's stated belief that current cash resources are sufficient to fund operations to profitability in 2026, along with improving financial metrics, could be viewed positively by creditors, reducing perceived risk.

Next Steps

• Continue accelerating VOQUEZNA's adoption through a refined commercial strategy focusing on high-value prescribers (GIs).
• Implement further cost reductions to achieve non-GAAP operating expenses less than $60 million for Q3 2025 and less than $55 million for Q4 2025.
• Work towards achieving profitability from operations in 2026.
• Host a conference call and webcast on August 7, 2025, at 8:00 a.m. EDT to discuss Q2 2025 financial results and business highlights.

Key Dates

Recommendation

The filing demonstrates strong operational execution and significant commercial momentum for VOQUEZNA, evidenced by substantial revenue growth and increasing prescription volumes. The extension of FDA New Chemical Entity exclusivity provides a long-term competitive advantage. Management's strategic cost reductions and clear guidance towards achieving profitability in 2026, supported by sufficient cash to reach that milestone, indicate a positive financial trajectory. While the company is still operating at a net loss and cash has decreased, the rate of improvement and the positive outlook suggest a compelling investment opportunity for growth-oriented investors.

Keywords

Phathom Pharmaceuticals, VOQUEZNA, GERD, H. pylori, Biopharmaceutical, Gastrointestinal diseases, Drug commercialization, Financial results, Prescription growth, Market exclusivity, Q2 2025 earnings, Pharmaceuticals, Biotech